Drugs / NCP-CD47 siRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07583914 | May 2026 → Jun 2027 expected | head and neck cancer, metastatic neoplasm | West China Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCP-CD47 siRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07583914 ↗ |
| Action | Inhibit | “candidate blocks the CD47-SIRPα "don't eat me" signal” NCT07583914 ↗ |
| Modality | Small interfering RNA (siRNA) | “NCP-CD47 siRNA” NCT07583914 ↗ |
| Route | Other | “administers the NCP-CD47 siRNA formulation via intratumoral injection” NCT07583914 ↗ |
| Target | CD47 | “candidate blocks the CD47-SIRPα "don't eat me" signal” NCT07583914 ↗ |